Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
11/01/17
Company Plans to Add 30 Highly Skilled Jobs in Dublin over Next Two Years DUBLIN , Nov. 1, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today announced the opening of a new corporate office in Dublin , further establishing the Company's presence in
10/31/17
Preliminary Findings Demonstrate Clinical Response Rates with VIBATIV® (telavancin) Treatment for Patients with Lower Respiratory Tract Infections DUBLIN , Oct. 31, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that
10/30/17
DUBLIN , Oct. 30, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended September 30, 2017 after market close on Tuesday, November 7, 2017 .
10/24/17
Preliminary Data from TOUR™ Observational Patient Registry Highlights Positive Clinical Response Rates for VIBATIV Against Lower Respiratory Tract Infections Revefenacin Presentations Highlight Additional Data from Two Pivotal Phase 3 Efficacy Studies in Patients with Moderate to Very Severe
10/09/17
Preliminary Data from TOUR™ Observational Patient Registry Demonstrate Clinical Response Rates with VIBATIV® (telavancin) Treatment Range from 64.9 - 72.6% for Patients with Bone and Joint Infections, Bacteremia and Infective Endocarditis Additional Study Results Demonstrate VIBATIV to be 8-Fold
10/03/17
Preliminary Data from TOUR™ Observational Patient Registry Highlights Positive Clinical Response Rates Against Bone and Joint Infections, Bacteremia and Infective Endocarditis Additional VIBATIV Study Results Demonstrate Greater in vitro Potency than Competitor Antibiotics Against
09/20/17
Single Inhaler Triple Therapy Met Study Primary Endpoint Demonstrating Reduction in Exacerbations Compared with Dual Therapies Anoro Ellipta and Relvar/Breo Ellipta in Patients with COPD Theravance Biopharma Entitled to Receive 85% Economic Interest in Trelegy Ellipta Royalties Paid by
09/19/17
DUBLIN , Sept. 19, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 9:10 a.m. ET .
09/19/17
Theravance Biopharma Entitled to Receive 85% Economic Interest in Trelegy Ellipta Royalties Paid by GlaxoSmithKline as Part of Agreement with Innoviva DUBLIN , Sept. 19, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that the US Food and
09/18/17
Theravance Biopharma Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement with Innoviva DUBLIN, Ireland , Sept. 18, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that GlaxoSmithKline plc